

Remarks

Applicants have amended the specification to correct a typographical error in the section entitled Related Applications. By this amendment claims 19, 26-29, 31, 37-44, 46-48, 50, 57-60, 68, 71-74, 81, 90, 97, and 106 are currently amended, no claims are canceled, and no new claims are added. No new matter is introduced.

The section entitled Related Applications is amended to correct the filing date of co-pending U.S. Patent Application serial number 09/818,918 from March 21, 2001, to March 27, 2001.

Claim 31 is currently amended to depend from claim 30, rather than from claim 84. This amendment is made to correct a typographical error in the dependency of claim 31.

Each of claims 38-44 and 46-48 is currently amended to depend from claim 37, rather than from claim 90. These amendments are made to correct typographical errors in the dependency of claims 38-44 and 46-48.

Each of claims 19, 37, 50, 68, 81, 90, 97, and 106 is currently amended to specify that the immunostimulatory nucleic acid molecule or immunomodulatory nucleic acid molecule comprises an unmethylated CpG dinucleotide. Support for this amended language can be found, for example, at page 7, lines 16-17.

Each of claims 26-29, 40-43, 57-60, and 71-74 is currently amended to specify that the immunostimulatory nucleic acid molecule is 8-100 nucleotides long. Support for this amended language can be found, for example, at page 14, lines 28 and 34.


All of the remarks in pages 15-19 of the Preliminary Amendment filed with the application on July 3, 2003, stand, as applied to claims 19-112 as amended herewith.

US 10/613,916

- 19 -

Art Unit 1632

Respectfully submitted,



Alan W. Steele, Reg. No. 45,128
WOLF, GREENFIELD & SACKS, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel.: (617) 720-3500

Docket No.: C1039.70075US00

Date: June 23, 2004

x06/23/04x